南華早報Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
作者 Shi Huang全文約 5,877 字
文章摘要
南華早報 · 文章頁摘要The treatment is already approved for some indications in China and could mark a shift in how cancers are treated, researchers say.
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medic...